Scientific Focus:
Apellis is committed to improving the lives of patients with geographic atrophy secondary to AMD and supports medical and scientific research that demonstrates the highest standards of scientific integrity, inclusivity, and intellectual curiosity. Submitted projects should focus on at least one of the following areas:
- Imaging and diagnostic strategies for GA
- Real-world insights on pegcetacoplan efficacy and safety
- Pegcetacoplan in underrepresented patient phenotypes
- Pegcetacoplan dosing strategies
Eligibility Requirements:
- All applicants should be entering or established within a vitreoretinal/medical retina fellowship.
- All proposed research projects should be completed within the timeframe of the applicants fellowship, no later than the end of July 2026.
- If conducting clinical research or research that involves patients, the investigator(s) license must be current and verifiable.
- The investigator(s) must not be excluded, debarred, suspended, or otherwise not eligible to participate in health care programs.
- The investigator(s) are not an employee of Apellis or its affiliated entities.
- As a condition of the grant, the selected fellow will be named in transparency reporting as a recipient of grant funding and any other related transfers of value.
Review Process:
Applications to the Apellis US Retina Fellow Research Grant will be reviewed on a rolling basis until the submission deadline. Applications will be de-identified and reviewed based on the research merit criteria and alignment with the Apellis scientific areas of interest.
Timeline:
Following closure of the submission portal on August 20, applications will be reviewed as outlined above. The process is anticipated to take 3-4 weeks, at which point the applicant with the selected submission will be notified. Following confirmation with the applicant, an announcement will be made regarding the selected project.